Type 1 Diabetes TrialNet: Clinical Centers (U01)

Post Date

December 29th 2008

Application Due Date

March 10th 2009

Funding Opportunity Number

RFA-DK-08-011

CFDA Number(s)

93.213
93.847
93.855
93.865

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Food and Nutrition
Health
Income Security and Social Services

Eligibility Categories

Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) .

Funding

• Estimated Total Funding:

  $5400000

• Award Range:

  $None - $None

Grant Description

Purpose. This FOA is being issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Center for Complementary and Alternative Medicine (NCCAM) to solicit applications to support clinical centers which will participate in studies aimed at preventing or delaying the onset or progression of type 1 diabetes (T1D) as part of the TrialNet clinical research network. TrialNet is working to achieve its goals through improving understanding of the natural history of the disease, screening and identifying persons at risk, and conducting clinical trials to evaluate promising new therapies that interdict the disease process. Most importantly, TrialNet evaluates new therapies, especially immunotherapies, in individuals (including children) who do not yet have clinical disease. To support the goal of prevention, TrialNet also performs studies that generate safety and efficacy information in individuals with newly-diagnosed diabetes. TrialNet tests interventions in patients with recent onset T1D to decrease b-cell destruction and/or enhance b-cell survival or regeneration in persons with T1D and residual b-cell function. In addition, TrialNet also evaluates methodologies to enhance the conduct of its clinical trials, which include tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies (studies to understand underlying pathophysiology) laying the foundation for future clinical trials.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-08-011.html